Switch theme
Sign up to access all valuation multiples
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
1982
1.2K+
LTM Revenue $289M
LTM EBITDA $1.2M
$696M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Staar Surgical has a last 12-month revenue (LTM) of $289M and a last 12-month EBITDA of $1.2M.
In the most recent fiscal year, Staar Surgical achieved revenue of $314M and an EBITDA of -$5.7M.
Staar Surgical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Staar Surgical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $289M | XXX | $314M | XXX | XXX | XXX |
| Gross Profit | $213M | XXX | $240M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $1.2M | XXX | -$5.7M | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -2% | XXX | XXX | XXX |
| EBIT | -$38.0M | XXX | -$12.6M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | -4% | XXX | XXX | XXX |
| Net Profit | -$42.6M | XXX | -$20.2M | XXX | XXX | XXX |
| Net Margin | -15% | XXX | -6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Staar Surgical's stock price is $18.
Staar Surgical has current market cap of $883M, and EV of $696M.
See Staar Surgical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $696M | $883M | XXX | XXX | XXX | XXX | $-0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Staar Surgical has market cap of $883M and EV of $696M.
Staar Surgical's trades at 2.2x EV/Revenue multiple, and -121.8x EV/EBITDA.
Equity research analysts estimate Staar Surgical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Staar Surgical has a P/E ratio of -20.7x.
See valuation multiples for Staar Surgical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $883M | XXX | $883M | XXX | XXX | XXX |
| EV (current) | $696M | XXX | $696M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 598.1x | XXX | -121.8x | XXX | XXX | XXX |
| EV/EBIT | -18.3x | XXX | -55.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -20.7x | XXX | -43.7x | XXX | XXX | XXX |
| EV/FCF | -29.4x | XXX | -90.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStaar Surgical's last 12 month revenue growth is -2%
Staar Surgical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Staar Surgical's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Staar Surgical's rule of X is -4% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Staar Surgical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Growth | -719% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 8% | XXX | -4% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -4% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 80% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Staar Surgical acquired XXX companies to date.
Last acquisition by Staar Surgical was XXXXXXXX, XXXXX XXXXX XXXXXX . Staar Surgical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Staar Surgical founded? | Staar Surgical was founded in 1982. |
| Where is Staar Surgical headquartered? | Staar Surgical is headquartered in United States of America. |
| How many employees does Staar Surgical have? | As of today, Staar Surgical has 1.2K+ employees. |
| Who is the CEO of Staar Surgical? | Staar Surgical's CEO is Mr. Stephen C. Farrell. |
| Is Staar Surgical publicy listed? | Yes, Staar Surgical is a public company listed on NAS. |
| What is the stock symbol of Staar Surgical? | Staar Surgical trades under STAA ticker. |
| When did Staar Surgical go public? | Staar Surgical went public in 1983. |
| Who are competitors of Staar Surgical? | Similar companies to Staar Surgical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Staar Surgical? | Staar Surgical's current market cap is $883M |
| What is the current revenue of Staar Surgical? | Staar Surgical's last 12 months revenue is $289M. |
| What is the current revenue growth of Staar Surgical? | Staar Surgical revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of Staar Surgical? | Current revenue multiple of Staar Surgical is 2.4x. |
| Is Staar Surgical profitable? | Yes, Staar Surgical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Staar Surgical? | Staar Surgical's last 12 months EBITDA is $1.2M. |
| What is Staar Surgical's EBITDA margin? | Staar Surgical's last 12 months EBITDA margin is 0%. |
| What is the current EV/EBITDA multiple of Staar Surgical? | Current EBITDA multiple of Staar Surgical is 598.1x. |
| What is the current FCF of Staar Surgical? | Staar Surgical's last 12 months FCF is -$23.7M. |
| What is Staar Surgical's FCF margin? | Staar Surgical's last 12 months FCF margin is -8%. |
| What is the current EV/FCF multiple of Staar Surgical? | Current FCF multiple of Staar Surgical is -29.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
